JP2022505637A5 - - Google Patents

Info

Publication number
JP2022505637A5
JP2022505637A5 JP2021522048A JP2021522048A JP2022505637A5 JP 2022505637 A5 JP2022505637 A5 JP 2022505637A5 JP 2021522048 A JP2021522048 A JP 2021522048A JP 2021522048 A JP2021522048 A JP 2021522048A JP 2022505637 A5 JP2022505637 A5 JP 2022505637A5
Authority
JP
Japan
Prior art keywords
compound
salt according
inhibitors
hiv
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021522048A
Other languages
English (en)
Japanese (ja)
Other versions
JP7532354B2 (ja
JP2022505637A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/059018 external-priority patent/WO2020084491A1/en
Publication of JP2022505637A publication Critical patent/JP2022505637A/ja
Publication of JP2022505637A5 publication Critical patent/JP2022505637A5/ja
Application granted granted Critical
Publication of JP7532354B2 publication Critical patent/JP7532354B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021522048A 2018-10-24 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤 Active JP7532354B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749801P 2018-10-24 2018-10-24
US62/749,801 2018-10-24
PCT/IB2019/059018 WO2020084491A1 (en) 2018-10-24 2019-10-22 Inhibitors of human immunodeficiency virus replication

Publications (3)

Publication Number Publication Date
JP2022505637A JP2022505637A (ja) 2022-01-14
JP2022505637A5 true JP2022505637A5 (https=) 2022-11-01
JP7532354B2 JP7532354B2 (ja) 2024-08-13

Family

ID=68344932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021522048A Active JP7532354B2 (ja) 2018-10-24 2019-10-22 ヒト免疫不全ウイルス複製の阻害剤

Country Status (5)

Country Link
US (1) US20210395262A1 (https=)
EP (1) EP3870576B1 (https=)
JP (1) JP7532354B2 (https=)
ES (1) ES2971987T3 (https=)
WO (1) WO2020084491A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3873607B1 (en) * 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) * 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
EP4066839A4 (en) 2019-11-28 2023-12-27 Shionogi & Co., Ltd PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS
US20250042926A1 (en) * 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
TW202547514A (zh) 2024-02-05 2025-12-16 英商Viiv醫療保健英國(No 5)有限公司 人類免疫不全病毒複製之抑制劑

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
CN119462611A (zh) * 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ, インコーポレイテッド ピリジン誘導体およびhiv感染を処置するためのその使用
EP3752496B1 (en) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection
EP3849982A1 (en) * 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7433303B2 (ja) * 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP7500555B2 (ja) * 2018-10-25 2024-06-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
JP2022506399A (ja) * 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication

Similar Documents

Publication Publication Date Title
JP2022505637A5 (https=)
JP2022505597A5 (https=)
JP2022505841A5 (https=)
JP2022505989A5 (https=)
JP2022500425A5 (https=)
JP2022501370A5 (https=)
ES2670769T3 (es) Derivados de (hetero)arilacetamida como agentes antirretrovirales
CA3089590A1 (en) Pyridine derivatives and their use for treating hiv infection
JP2006506425A5 (https=)
JP2022081661A5 (https=)
JP2017533895A5 (https=)
RU2001132635A (ru) Производные пиперидина, применимые в качестве антагонистов сс R5
JP2020507589A5 (https=)
JP2008508214A (ja) 女性の性障害の治療用ピペラジン誘導体
JP2023544716A5 (https=)
JP2023512664A5 (https=)
JP2025508656A5 (https=)
TW202237146A (zh) 使用腺苷衍生物及衣殼抑制劑之hiv組合療法
JPWO2023054292A5 (https=)
CN110612286A (zh) 氰基取代的稠合双环衍生物及其制备方法和用途
RU2007105582A (ru) Агонисты рецепторов никотина и способы их применения для лечения воспалительных заболеваний
CN100475209C (zh) 抗冠状病毒剂
JP2024507550A5 (https=)
DK3107906T3 (en) REDUCED CENTRAL CORNER MAP THICKNESS USING HYDROFILE ESTER PRODRUGS OF BETA-CHLORCYCLOPENTANE
JP2025507308A5 (https=)